Solventum Corporation $SOLV Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp decreased its position in Solventum Corporation (NYSE:SOLV) by 4.2% in the first quarter, Holdings Channel reports. The institutional investor owned 777,005 shares of the company’s stock after selling 33,928 shares during the period. Bank of New York Mellon Corp’s holdings in Solventum were worth $50,738,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of SOLV. Sanctuary Advisors LLC raised its holdings in Solventum by 22.1% in the 1st quarter. Sanctuary Advisors LLC now owns 32,664 shares of the company’s stock worth $2,133,000 after purchasing an additional 5,915 shares during the period. Principal Financial Group Inc. boosted its position in Solventum by 3.2% during the first quarter. Principal Financial Group Inc. now owns 167,833 shares of the company’s stock worth $10,959,000 after purchasing an additional 5,145 shares in the last quarter. Diversify Wealth Management LLC grew its holdings in Solventum by 29.3% in the first quarter. Diversify Wealth Management LLC now owns 4,694 shares of the company’s stock valued at $312,000 after purchasing an additional 1,065 shares during the period. General American Investors Co. Inc. grew its holdings in Solventum by 6.4% in the first quarter. General American Investors Co. Inc. now owns 377,350 shares of the company’s stock valued at $24,641,000 after purchasing an additional 22,700 shares during the period. Finally, Fifth Third Bancorp increased its position in shares of Solventum by 1,749.4% in the first quarter. Fifth Third Bancorp now owns 67,856 shares of the company’s stock valued at $4,431,000 after buying an additional 64,187 shares in the last quarter.

Solventum Stock Performance

Shares of Solventum stock opened at $77.29 on Friday. The business’s 50 day moving average price is $77.39 and its 200 day moving average price is $74.20. The company has a market cap of $13.39 billion, a price-to-earnings ratio of 9.47, a PEG ratio of 1.20 and a beta of 0.66. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. Solventum Corporation has a one year low of $62.38 and a one year high of $88.20.

Solventum (NYSE:SOLV) last issued its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same period last year, the company earned $1.34 EPS. The company’s revenue for the quarter was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, research analysts predict that Solventum Corporation will post 6.58 EPS for the current year.

Analysts Set New Price Targets

SOLV has been the topic of several recent analyst reports. BMO Capital Markets initiated coverage on shares of Solventum in a report on Wednesday, July 8th. They set a “market perform” rating and a $81.00 price objective on the stock. Stifel Nicolaus cut their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. BTIG Research restated a “buy” rating and set a $91.00 price target on shares of Solventum in a research report on Monday, July 13th. Wells Fargo & Company reduced their price target on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 6th. Finally, Weiss Ratings raised shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 17th. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Solventum has a consensus rating of “Hold” and a consensus target price of $81.91.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.